| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.45 | 53.21 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 11.82B | 44.08 | 25.05 | 18.49% | 29.63% | 31.37% | 5.36% | 0.09 |
| INBXInhibrx Biosciences, Inc. | 1.07B | 73.28 | 0.63 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.24B | 6.55 | -3.10 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.38B | 7.94 | -3.36 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 987.53M | 10.14 | -5.54 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.07B | 18.72 | -7.20 | 49.59% | -46.83% | -27.21% | 0.18 | |
| TNGXTango Therapeutics, Inc. | 1.41B | 10.44 | -8.77 | 15.17% | -151.15% | -62.81% | 0.18 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 195.14K | 3.48M | 5.21M | 7.6M | 160.1M | 502.55M | 783.21M |
| Revenue Growth % | - | - | 16.86% | 0.5% | 0.46% | 20.08% | 2.14% | 0.56% |
| Cost of Goods Sold | 3.79K | 0 | 15.36M | 22.09M | 37.36M | 130.76M | 188.16M | 273.53M |
| COGS % of Revenue | - | - | 4.41% | 4.24% | 4.92% | 0.82% | 0.37% | 0.35% |
| Gross Profit | -3.79K | 195.14K | -11.88M | -16.88M | -29.77M | 29.34M | 314.39M | 509.68M |
| Gross Margin % | - | 1% | -3.41% | -3.24% | -3.92% | 0.18% | 0.63% | 0.65% |
| Gross Profit Growth % | - | 52.45% | -61.85% | -0.42% | -0.76% | 1.99% | 9.72% | 0.62% |
| Operating Expenses | 6.52M | 27.85M | 28.38M | 47.56M | 81.12M | 102.52M | 263.27M | 427.55M |
| OpEx % of Revenue | - | 142.71% | 8.14% | 9.12% | 10.68% | 0.64% | 0.52% | 0.55% |
| Selling, General & Admin | 2.67M | 9.08M | 11.59M | 19.21M | 46.99M | 87.1M | 134.16M | 207.13M |
| SG&A % of Revenue | - | 46.52% | 3.32% | 3.68% | 6.19% | 0.54% | 0.27% | 0.26% |
| Research & Development | 2.98M | 18.69M | 21.16M | 23.09M | 34.13M | 57.86M | 128.84M | 121.03M |
| R&D % of Revenue | - | 95.79% | 6.07% | 4.43% | 4.49% | 0.36% | 0.26% | 0.15% |
| Other Operating Expenses | 112.64K | 0 | -4.37M | 5.27M | 0 | -42.44M | 270K | 99.39M |
| Operating Income | -6.37M | -15.68M | -40.26M | -49.25M | -81.25M | -91.93M | 51.89M | 82.13M |
| Operating Margin % | - | -80.38% | -11.55% | -9.45% | -10.7% | -0.57% | 0.1% | 0.1% |
| Operating Income Growth % | - | -1.46% | -1.57% | -0.22% | -0.65% | -0.13% | 1.56% | 0.58% |
| EBITDA | -6.36M | -15.68M | -36.02M | -44.94M | -76.07M | -86.55M | 58.63M | 87.82M |
| EBITDA Margin % | - | -80.34% | -10.34% | -8.62% | -10.01% | -0.54% | 0.12% | 0.11% |
| EBITDA Growth % | - | -1.46% | -1.3% | -0.25% | -0.69% | -0.14% | 1.68% | 0.5% |
| D&A (Non-Cash Add-back) | 3.79K | 6.93K | 4.24M | 4.31M | 5.17M | 5.38M | 6.74M | 5.69M |
| EBIT | -6.77M | -15.68M | -28.71M | -49.25M | -75.25M | -98.22M | 16.22M | 92.55M |
| Net Interest Income | 29.58K | 303.73K | -2.31M | -1.11M | -163K | -405K | -12.74M | -10.6M |
| Interest Income | 38.98K | 332.75K | 98K | 67K | 163K | 1K | 694.25K | 10.86M |
| Interest Expense | 9.4K | 29.02K | 2.41M | 1.18M | 189K | 406K | 13.56M | 21.46M |
| Other Income/Expense | 142.22K | 11.94M | 0 | -11M | -17.79M | -6.69M | 0 | -26.07M |
| Pretax Income | -6.38M | -15.71M | -42.81M | -60.25M | -99.04M | -98.62M | 3.09M | 56.06M |
| Pretax Margin % | - | -80.53% | -12.29% | -11.56% | -13.04% | -0.62% | 0.01% | 0.07% |
| Income Tax | 9.4K | -1.88M | -14.95M | -15.37M | -18.53M | 5.46M | -2.12M | 6.14M |
| Effective Tax Rate % | 1% | 0.88% | 0.65% | 0.74% | 0.81% | 1.06% | 1.69% | 0.89% |
| Net Income | -6.38M | -13.83M | -27.87M | -44.89M | -80.51M | -104.08M | 5.21M | 49.92M |
| Net Margin % | - | -70.87% | -8% | -8.61% | -10.6% | -0.65% | 0.01% | 0.06% |
| Net Income Growth % | - | -1.17% | -1.01% | -0.61% | -0.79% | -0.29% | 1.05% | 8.58% |
| Net Income (Continuing) | -6.38M | -13.83M | -27.87M | -44.89M | -80.51M | -104.08M | 5.21M | 49.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05 | -0.07 | -0.12 | -0.17 | -0.29 | -0.34 | 0.02 | 0.14 |
| EPS Growth % | - | -0.37% | -0.75% | -0.42% | -0.71% | -0.17% | 1.05% | 7.7% |
| EPS (Basic) | -0.05 | -0.07 | -0.12 | -0.17 | -0.29 | -0.34 | 0.02 | 0.15 |
| Diluted Shares Outstanding | 127.99M | 202.12M | 233.44M | 257.27M | 282.21M | 310.64M | 323.71M | 345.19M |
| Basic Shares Outstanding | 127.99M | 202.12M | 233.44M | 257.27M | 282.21M | 310.64M | 319.18M | 331.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 49.55M | 35.86M | 58.68M | 93.63M | 47.54M | 173.23M | 224.85M | 918.56M |
| Cash & Short-Term Investments | 48.76M | 25.77M | 44.6M | 77.94M | 22.04M | 79.14M | 123.24M | 710.35M |
| Cash Only | 48.76M | 25.77M | 44.6M | 77.94M | 22.04M | 116.33M | 123.24M | 710.35M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 488.83K | 8.97M | 13.01M | 14.19M | 20.84M | 31.14M | 79.53M | 158.99M |
| Days Sales Outstanding | - | 16.78K | 1.36K | 993.62 | 1K | 71 | 57.77 | 74.1 |
| Inventory | 297.22K | 642.52K | 542K | 633K | 3.45M | 5.77M | 17.31M | 38.14M |
| Days Inventory Outstanding | 28.6K | - | 12.88 | 10.46 | 33.74 | 16.1 | 33.58 | 50.9 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 55.48M | -7.66M | 0 |
| Total Non-Current Assets | 1.55M | 40.85M | 43.93M | 70.81M | 62.27M | 87.36M | 173.45M | 597.87M |
| Property, Plant & Equipment | 5.39K | 226.17K | 1.9M | 4.82M | 6.33M | 18.84M | 30.49M | 54.32M |
| Fixed Asset Turnover | - | 0.86x | 1.84x | 1.08x | 1.20x | 8.50x | 16.48x | 14.42x |
| Goodwill | 332.49K | 3.14M | 4.22M | 4.22M | 4.1M | 5.52M | 4.85M | 106.65M |
| Intangible Assets | 1.18M | 36.31M | 41.95M | 59.19M | 55.73M | 58.98M | 104.82M | 309.49M |
| Long-Term Investments | 0 | 1.14M | 0 | -4.22M | 0 | -5.52M | 12.26M | 6.09M |
| Other Non-Current Assets | 35.29K | 1.17M | -4.14M | 183K | -3.88M | 327K | 586K | 74.58M |
| Total Assets | 51.09M | 76.71M | 102.61M | 157.82M | 109.81M | 260.59M | 398.3M | 1.52B |
| Asset Turnover | - | 0.00x | 0.03x | 0.03x | 0.07x | 0.61x | 1.26x | 0.52x |
| Asset Growth % | - | 0.5% | 0.34% | 0.54% | -0.3% | 1.37% | 0.53% | 2.81% |
| Total Current Liabilities | 1.47M | 8.24M | 10.63M | 19.96M | 37.98M | 85.56M | 157.41M | 330.91M |
| Accounts Payable | 275.84K | 3.25M | 6.96M | 5.81M | 11.88M | 16.81M | 32.84M | 68.7M |
| Days Payables Outstanding | 26.54K | - | 165.49 | 95.97 | 116.1 | 46.91 | 63.7 | 91.67 |
| Short-Term Debt | 345.43K | 1.13M | 469K | 264K | 19K | 0 | 964K | 18.99M |
| Deferred Revenue (Current) | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 847.17K | 3.38M | 2.72M | 7.65M | 14.12M | 47.33M | 85.7M | 109.67M |
| Current Ratio | 33.74x | 4.35x | 5.52x | 4.69x | 1.25x | 2.02x | 1.43x | 2.78x |
| Quick Ratio | 33.54x | 4.27x | 5.47x | 4.66x | 1.16x | 1.96x | 1.32x | 2.66x |
| Cash Conversion Cycle | - | - | 1.21K | 908.11 | 919.28 | 40.18 | 27.65 | 33.32 |
| Total Non-Current Liabilities | 332.49K | 15.56M | 21.25M | 64.49M | 68.19M | 92.88M | 91.98M | 617.31M |
| Long-Term Debt | 0 | 596.29K | 292K | 95K | 0 | 3.31M | 8.21M | 551.82M |
| Capital Lease Obligations | 0 | 0 | 1.35M | 1.34M | 1.91M | 6.49M | 7.68M | 8.14M |
| Deferred Tax Liabilities | 332.49K | 4.37M | 3.17M | 6.62M | 0 | 5.24M | 3.92M | 9.38M |
| Other Non-Current Liabilities | 0 | 10.59M | 16.44M | 57.41M | 43.23M | 55.31M | 60.02M | 44.67M |
| Total Liabilities | 1.8M | 23.8M | 31.88M | 78.81M | 106.17M | 175.35M | 249.39M | 948.22M |
| Total Debt | 345.43K | 1.73M | 2.13M | 2.21M | 2.54M | 10.45M | 17.45M | 581.45M |
| Net Debt | -48.41M | -24.04M | -42.47M | -75.74M | -19.5M | -105.88M | -105.79M | -128.9M |
| Debt / Equity | 0.01x | 0.03x | 0.03x | 0.03x | 1.18x | 0.13x | 0.12x | 1.02x |
| Debt / EBITDA | - | - | - | - | - | - | 0.30x | 6.62x |
| Net Debt / EBITDA | - | - | - | - | - | - | -1.80x | -1.47x |
| Interest Coverage | -677.34x | -540.52x | -16.72x | -41.92x | -429.88x | -226.43x | 3.83x | 3.83x |
| Total Equity | 49.29M | 52.9M | 70.08M | 79.02M | 2.16M | 80.01M | 148.91M | 568.21M |
| Equity Growth % | - | 0.07% | 0.32% | 0.13% | -0.97% | 36.07% | 0.86% | 2.82% |
| Book Value per Share | 0.39 | 0.26 | 0.30 | 0.31 | 0.01 | 0.26 | 0.46 | 1.65 |
| Total Shareholders' Equity | 49.29M | 52.9M | 70.08M | 79.02M | 2.16M | 80.01M | 148.91M | 568.21M |
| Common Stock | 55.56M | 72.05M | 115.94M | 167.06M | 170.84M | 370.97M | 446.27M | 596.78M |
| Retained Earnings | -6.38M | -20.21M | -48.07M | -92.96M | -173.47M | -272.81M | -263.67M | -212.96M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 109K | 1.06M | 2.21M | 4.92M | 4.79M | -18.15M | -33.69M | 184.4M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.03M | -20.75M | -23.33M | 1.96M | -59.33M | -63.97M | 23.88M | 43.03M |
| Operating CF Margin % | - | -106.32% | -6.7% | 0.38% | -7.81% | -0.4% | 0.05% | 0.05% |
| Operating CF Growth % | - | -2.44% | -0.12% | 1.08% | -31.27% | -0.08% | 1.37% | 0.8% |
| Net Income | -6.38M | -13.83M | -27.87M | -44.89M | -80.51M | -104.08M | 5.21M | 0 |
| Depreciation & Amortization | 3.79K | 6.97K | 4.24M | 4.88M | 5.17M | 5.38M | 6.92M | 0 |
| Stock-Based Compensation | 109.02K | 712K | 1.27M | 2.35M | 1.32M | 8.11M | 8.79M | 0 |
| Deferred Taxes | -6.37M | -17.19M | -10.3M | -10.86M | -14.2M | -13.38M | 0 | 0 |
| Other Non-Cash Items | 0 | 13.82M | 9.69M | 18.66M | 31.52M | 41M | 60.5M | 107.3M |
| Working Capital Changes | 232.79K | -4.27M | -361K | 31.81M | -2.63M | -1.01M | -57.53M | -64.27M |
| Change in Receivables | -338.8K | -7.22M | -3.63M | -328K | -7.19M | -19.93M | -27.38M | 0 |
| Change in Inventory | 0 | 0 | 101K | -91K | -2.82M | -5.02M | -9.64M | 0 |
| Change in Payables | 1.12M | 4.44M | 2.98M | 1.67M | 7.48M | 30.45M | 0 | 0 |
| Cash from Investing | -1.26K | -2.69M | -468K | -1.09M | -2.73M | -17M | -25.49M | -135.17M |
| Capital Expenditures | -5.64K | 0 | -468K | -322K | -1.34M | -13.86M | -9.68M | -14.32M |
| CapEx % of Revenue | - | - | 0.13% | 0.06% | 0.18% | 0.09% | 0.02% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -447K | -1.39M | -2.16M | -1.17M | -34.17M |
| Cash from Financing | 54.79M | -869.35K | 42.72M | 34.12M | 2.85M | 174.96M | 10.19M | 638.92M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | -54.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -1.59M | -502K | -596K | -1.26M | -2.22M | -14.88M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -6.04M | -20.75M | -23.8M | 1.64M | -60.67M | -77.83M | 13.09M | 9M |
| FCF Margin % | - | -106.32% | -6.83% | 0.31% | -7.99% | -0.49% | 0.03% | 0.01% |
| FCF Growth % | - | -2.44% | -0.15% | 1.07% | -38.04% | -0.28% | 1.17% | -0.31% |
| FCF per Share | -0.05 | -0.10 | -0.10 | 0.01 | -0.21 | -0.25 | 0.04 | 0.03 |
| FCF Conversion (FCF/Net Income) | 0.95x | 1.50x | 0.84x | -0.04x | 0.74x | 0.61x | 4.58x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 408K | 785K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 2.28M | 10.25M | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -12.94% | -27.07% | -45.32% | -60.21% | -198.36% | -253.34% | 4.55% | 13.92% |
| Return on Invested Capital (ROIC) | -543.15% | -79.11% | -106.92% | -239.15% | - | - | 451.37% | 25.54% |
| Gross Margin | - | 100% | -340.75% | -323.75% | -391.85% | 18.32% | 62.56% | 65.08% |
| Net Margin | - | -7087.06% | -799.63% | -861.06% | -1059.9% | -65.01% | 1.04% | 6.37% |
| Debt / Equity | 0.01x | 0.03x | 0.03x | 0.03x | 1.18x | 0.13x | 0.12x | 1.02x |
| Interest Coverage | -677.34x | -540.52x | -16.72x | -41.92x | -429.88x | -226.43x | 3.83x | 3.83x |
| FCF Conversion | 0.95x | 1.50x | 0.84x | -0.04x | 0.74x | 0.61x | 4.58x | 0.86x |
| Revenue Growth | - | - | 1685.88% | 49.58% | 45.71% | 2007.64% | 213.9% | 55.85% |
| 2013 | 2018 | 2024 | |
|---|---|---|---|
| Digital Product Sales | - | 35.87M | - |
| Digital Product Sales Growth | - | - | - |
| Digital Product Lease And Maintenance | - | 4.88M | - |
| Digital Product Lease And Maintenance Growth | - | - | - |
| Digital Display Sales | 14.61M | - | - |
| Digital Display Sales Growth | - | - | - |
| Digital Display Lease And Maintenance | 6.3M | - | - |
| Digital Display Lease And Maintenance Growth | - | - | - |
| 2013 | 2018 | 2024 | |
|---|---|---|---|
| UNITED STATES | - | - | 762.31M |
| UNITED STATES Growth | - | - | - |
| CANADA | - | - | 2.54M |
| CANADA Growth | - | - | - |
| AUSTRALIA | - | - | 1.22M |
| AUSTRALIA Growth | - | - | - |
| BELGIUM | - | - | 546K |
| BELGIUM Growth | - | - | - |
Telix Pharmaceuticals Limited (TLX) has a price-to-earnings (P/E) ratio of 53.2x. This suggests investors expect higher future growth.
Telix Pharmaceuticals Limited (TLX) reported $1.66B in revenue for fiscal year 2024.
Telix Pharmaceuticals Limited (TLX) grew revenue by 55.8% over the past year. This is strong growth.
Yes, Telix Pharmaceuticals Limited (TLX) is profitable, generating $66.0M in net income for fiscal year 2024 (6.4% net margin).
Telix Pharmaceuticals Limited (TLX) has a return on equity (ROE) of 13.9%. This is reasonable for most industries.
Telix Pharmaceuticals Limited (TLX) generated $28.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.